From GlobeNewswire: 2025-04-25 16:30:00

Rezolute, Inc. announced the closing of its underwritten offering, raising approximately $96.9 million through the sale of 24,940,769 shares of common stock at $3.25 per share. Investors included Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Great Point Partners, among others. Guggenheim Securities acted as the sole book-running manager for the Offering. In addition, existing investors have committed to purchase up to an additional $4.2 million shares of common stock in a separate private placement. The Company’s antibody therapy, ersodetug, aims to improve outcomes for individuals with hypoglycemia caused by hyperinsulinism.



Read more at GlobeNewswire: Rezolute, Inc. Announces Closing of Underwritten Offering